Loading...

We've got a brand new version of Simply Wall St! Try it out

BioGend Therapeutics

GTSM:6733
Snowflake Description

Flawless balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
6733
GTSM
NT$2B
Market Cap
  1. Home
  2. TW
  3. Pharmaceuticals & Biotech
Company description

BioGend Therapeutics Co., Ltd. develops regenerative bio-orthopaedic medicines. The last earnings update was 104 days ago. More info.


Add to Portfolio Compare Print
6733 Share Price and Events
7 Day Returns
1.8%
GTSM:6733
-2%
TW Biotechs
0.7%
TW Market
1 Year Returns
-
GTSM:6733
-11.1%
TW Biotechs
19.1%
TW Market
6733 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
BioGend Therapeutics (6733) 1.8% 5.2% -8.2% - - -
TW Biotechs -2% -4.4% -7.3% -11.1% -42.7% -41.3%
TW Market 0.7% 3.5% 9.4% 19.1% 25.5% 26.5%
1 Year Return vs Industry and Market
  • No trading data on 6733.
  • No trading data on 6733.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

Sorry, no analysis for BioGend Therapeutics's competitors could be found in our database.

6733 Value

 Is BioGend Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for BioGend Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is NT$27.99.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for BioGend Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are BioGend Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
GTSM:6733 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in TWD NT$-2.25
GTSM:6733 Share Price ** GTSM (2019-11-20) in TWD NT$27.99
Taiwan, Province of China Biotechs Industry PE Ratio Median Figure of 8 Publicly-Listed Biotechs Companies 33.52x
Taiwan, Province of China Market PE Ratio Median Figure of 1,425 Publicly-Listed Companies 16.64x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of BioGend Therapeutics.

GTSM:6733 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= GTSM:6733 Share Price ÷ EPS (both in TWD)

= 27.99 ÷ -2.25

-12.46x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BioGend Therapeutics is loss making, we can't compare its value to the TW Biotechs industry average.
  • BioGend Therapeutics is loss making, we can't compare the value of its earnings to the Taiwan, Province of China market.
Price based on expected Growth
Does BioGend Therapeutics's expected growth come at a high price?
Raw Data
GTSM:6733 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -12.46x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Asia Biotechs Industry PEG Ratio Median Figure of 28 Publicly-Listed Biotechs Companies 1.66x
Taiwan, Province of China Market PEG Ratio Median Figure of 248 Publicly-Listed Companies 1.07x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for BioGend Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on BioGend Therapeutics's assets?
Raw Data
GTSM:6733 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in TWD NT$8.27
GTSM:6733 Share Price * GTSM (2019-11-20) in TWD NT$27.99
Taiwan, Province of China Biotechs Industry PB Ratio Median Figure of 40 Publicly-Listed Biotechs Companies 3.1x
Taiwan, Province of China Market PB Ratio Median Figure of 1,938 Publicly-Listed Companies 1.44x
GTSM:6733 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= GTSM:6733 Share Price ÷ Book Value per Share (both in TWD)

= 27.99 ÷ 8.27

3.39x

* Primary Listing of BioGend Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BioGend Therapeutics is overvalued based on assets compared to the TW Biotechs industry average.
X
Value checks
We assess BioGend Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. BioGend Therapeutics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

6733 Future Performance

 How is BioGend Therapeutics expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as BioGend Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
30.4%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is BioGend Therapeutics expected to grow at an attractive rate?
  • Unable to compare BioGend Therapeutics's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare BioGend Therapeutics's earnings growth to the Taiwan, Province of China market average as no estimate data is available.
  • Unable to compare BioGend Therapeutics's revenue growth to the Taiwan, Province of China market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
GTSM:6733 Future Growth Rates Data Sources
Data Point Source Value (per year)
Asia Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 30.4%
Taiwan, Province of China Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 61.4%
Taiwan, Province of China Market Earnings Growth Rate Market Cap Weighted Average 13.4%
Taiwan, Province of China Market Revenue Growth Rate Market Cap Weighted Average 8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
GTSM:6733 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in TWD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
GTSM:6733 Past Financials Data
Date (Data in TWD Millions) Revenue Cash Flow Net Income *
2019-06-30 1 -147 -164
2019-03-31 0 -146 -166
2018-12-31 -145 -167
2017-12-31 -151 -130
2016-12-31 -76 -136

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if BioGend Therapeutics is high growth as no earnings estimate data is available.
  • Unable to determine if BioGend Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
GTSM:6733 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from BioGend Therapeutics Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

GTSM:6733 Past Financials Data
Date (Data in TWD Millions) EPS *
2019-06-30 -2.25
2019-03-31 -2.48
2018-12-31 -2.76
2017-12-31 -2.98
2016-12-31 -5.43

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if BioGend Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine BioGend Therapeutics's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. BioGend Therapeutics's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess BioGend Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Asia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Taiwan, Province of China market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
BioGend Therapeutics has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

6733 Past Performance

  How has BioGend Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare BioGend Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • BioGend Therapeutics does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare BioGend Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare BioGend Therapeutics's 1-year growth to the TW Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
BioGend Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from BioGend Therapeutics Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

GTSM:6733 Past Revenue, Cash Flow and Net Income Data
Date (Data in TWD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 0.57 -164.08 35.41 129.00
2019-03-31 0.28 -165.77 35.15 130.16
2018-12-31 -167.46 34.89 131.31
2017-12-31 -129.58 10.03 134.41
2016-12-31 -135.73 5.23 130.51

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if BioGend Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if BioGend Therapeutics has efficiently used its assets last year compared to the TW Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if BioGend Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess BioGend Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
BioGend Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

6733 Health

 How is BioGend Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up BioGend Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • BioGend Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • BioGend Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of BioGend Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • BioGend Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from BioGend Therapeutics Company Filings, last reported 4 months ago.

GTSM:6733 Past Debt and Equity Data
Date (Data in TWD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 677.93 0.00 490.03
2019-03-31 677.93 0.00 490.03
2018-12-31 632.17 0.00 440.14
2017-12-31 357.54 60.31 220.65
2016-12-31 182.13 0.00 106.11
  • BioGend Therapeutics has no debt.
  • BioGend Therapeutics currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • BioGend Therapeutics has sufficient cash runway for more than 3 years based on current free cash flow.
  • BioGend Therapeutics has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 2.6% each year.
X
Financial health checks
We assess BioGend Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. BioGend Therapeutics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

6733 Dividends

 What is BioGend Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from BioGend Therapeutics dividends.
If you bought NT$2,000 of BioGend Therapeutics shares you are expected to receive NT$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate BioGend Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate BioGend Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
GTSM:6733 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Taiwan, Province of China Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 3%
Taiwan, Province of China Market Average Dividend Yield Market Cap Weighted Average of 1324 Stocks 4.1%
Taiwan, Province of China Minimum Threshold Dividend Yield 10th Percentile 1.5%
Taiwan, Province of China Bottom 25% Dividend Yield 25th Percentile 2.6%
Taiwan, Province of China Top 25% Dividend Yield 75th Percentile 5.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as BioGend Therapeutics has not reported any payouts.
  • Unable to verify if BioGend Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of BioGend Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as BioGend Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess BioGend Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.5%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can BioGend Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. BioGend Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

6733 Management

 What is the CEO of BioGend Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
  • BioGend Therapeutics has no CEO, or we have no data on them.
Management Team
Board of Directors
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (NT$) Value (NT$)
X
Management checks
We assess BioGend Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. BioGend Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

6733 News

Simply Wall St News

6733 Company Info

Description

BioGend Therapeutics Co., Ltd. develops regenerative bio-orthopaedic medicines. It is developing BiG-001 and BiG-006, an osteo-inductive bone graft substitute; and BiG-009, an autologous chondrocyte repair system. The company is also involved in developing bio-orthopaedic devices and treatment methods to fulfill unmet clinical needs. BioGend Therapeutics Co., Ltd. was founded in 2016 and is based in Taipei City, Taiwan.

Details
Name: BioGend Therapeutics Co., Ltd.
6733
Exchange: GTSM
Founded: 2016
NT$2,295,180,000
82,000,000
Website: http://www.biogend.com.tw
Address: BioGend Therapeutics Co., Ltd.
No.3-2, Park ST.,
4th Floor,
Taipei City,
115,
Taiwan
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
GTSM 6733 Share Capital Taipei Exchange TW TWD 18. Jun 2019
Number of employees
Current staff
Staff numbers
27
BioGend Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/20 16:18
End of day share price update: 2019/11/20 00:00
Last earnings filing: 2019/08/08
Last earnings reported: 2019/06/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.